Novavax, Inc. has amended its existing agreement with Serum Institute of India Private Ltd. (SIIPL) under which SIIPL will also manufacture the antigen component of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate. With this agreement, Novavax increases its manufacturing capacity of NVX-CoV2373 to over two billion doses annually, when all planned capacity has been brought online by mid-2021. NVX‑CoV2373 is a stable, prefusion protein made using Novavax’ recombinant protein nanoparticle technology and includes Novavax’ Matrix‑M adjuvant.

The agreement with SIIPL augments a global supply chain that will deliver over two billion doses of NVX-CoV2373 annually as of 2021.

The antigen component of NVX-CoV2373 is being manufactured at Novavax CZ in Bohumil, Czech Republic (formerly Praha Vaccines), as well as partnered manufacturing with:

Biofabri in Spain

FUJIFILM Diosynth Biotechnologies in both NC and TX in the U.S.

FDB in the UK

SIIPL in India

SK Bioscience in the Republic of Korea

Takeda Pharmaceutical Company in Japan
 

Novavax’ Matrix-M adjuvant is now being manufactured at Novavax AB in Uppsala, Sweden and the following partnered manufacturing sites:

AGC Biologics in the U.S. and Denmark

PolyPeptide Group will manufacture two key intermediaries used in Matrix-M in the U.S. and Sweden